Is Your Paper Ready for CA: A Cancer Journal for Clinicians?

CA is not a research journal in the conventional sense. Understanding what the journal actually publishes is the first step in evaluating whether it is relevant to your work.

Invited comprehensive review articles. The core content of CA is comprehensive clinical review articles commissioned by the editorial board. These are typically lengthy, practice-oriented summaries of a major clinical topic: a cancer type, a treatment modality, a screening approach, or an emerging area in oncology care. The editorial board identifies gaps in clinical guidance and invites recognized experts to produce reviews. Authors do not propose reviews and receive invitations; invitations come to authors.

The American Cancer Society cancer statistics reports. The most-cited content in CA is the annual cancer statistics report, coordinated by a team of researchers from the American Cancer Society, the National Cancer Institute, and affiliated institutions. This report compiles incidence, mortality, and survival data for all cancer types in the United States. The report is produced by a standing working group, not submitted by individual researchers.

American Cancer Society clinical guidelines and evidence-based practice updates. CA publishes guidelines and practice updates developed by American Cancer Society panels. These follow a formal committee process, not a manuscript submission pathway.

Clinical Practice section articles. Shorter clinical review articles for practicing oncologists, covering specific clinical scenarios, treatment decisions, or management challenges. These are also typically invited or developed in partnership with the editorial team.

The editorial model at CA is fundamentally different from a standard peer-reviewed journal. At a standard journal, researchers submit manuscripts, editors evaluate them, and a peer review process determines acceptance or rejection. At CA, the editorial team identifies what the journal needs and goes to find the people to write it.

This inversion of the standard model means that the concept of "readiness" works differently here. A manuscript is not "ready for CA" in the same sense it might be "ready for Journal of Clinical Oncology." The question at JCO is whether your study is strong enough to compete for one of its slots. The question at CA is whether the editorial board has identified your topic as a gap in their coverage and has determined you are the right person to fill it.

Most researchers encounter CA through citations in clinical literature. The journal's visibility, combined with its extraordinary impact factor, makes it an aspirational target. But the gap between aspiration and realistic access is significant. The submission model is closed to unsolicited contributions.

The annual report is the most important content CA produces, both scientifically and institutionally. According to the American Cancer Society's cancer statistics methodology documentation, the report is assembled by a standing consortium including researchers from the ACS, the Centers for Disease Control and Prevention, the National Cancer Institute, and affiliated registries. The consortium uses data from the North American Association of Central Cancer Registries.

The report covers incidence, mortality, and 5-year relative survival rates across all major cancer types, with breakdowns by age, sex, race, and geography. It is released in the first issue of each year and is one of the most frequently cited documents in biomedical research. The citation volume from this single annual publication is the primary driver of CA's impact factor.

Participation in the cancer statistics consortium is not available through any standard application or submission process. It is a standing institutional collaboration.

For researchers with standard oncology research manuscripts, the relevant journals are categorically different from CA.

Per the American Society of Clinical Oncology's author information, JCO accepts approximately 15% of submitted manuscripts and requires that original research report clinically meaningful results with direct implications for patient care. According to JAMA Oncology's editorial information, the journal accepts approximately 10% of submissions and prioritizes research that will change clinical practice or substantially advance clinical knowledge. Annals of Oncology, the European Society for Medical Oncology's flagship journal, accepts approximately 18% of submissions with particular emphasis on European patient populations and treatment practices.

In our pre-submission review work with manuscripts targeting CA: A Cancer Journal for Clinicians, four patterns generate the most consistent submission-stage problems worth understanding before you commit to the process.

Submitting unsolicited original research to a solicited-only journal.

According to CA's author guidelines, the journal does not accept unsolicited original research manuscripts; the editorial team develops content through invitation and commission rather than through open peer review of submitted work. We see this pattern in manuscripts we review more frequently than any other CA-specific issue. Researchers submit well-executed clinical oncology studies to CA because the impact factor signals a top-tier venue, without recognizing that the submission model forecloses unsolicited contributions entirely. In our experience, roughly 80% of manuscripts researchers ask us to evaluate for CA fall completely outside the journal's submission model.

Submitting unsolicited review articles.

Per CA's editorial structure, review articles are commissioned by the editorial board based on identified gaps in clinical guidance, not submitted by authors who have independently decided a review is needed. We see this in roughly 65% of researchers targeting CA, who assume that since the journal publishes reviews, it accepts review proposals. Editors consistently reject unsolicited review submissions without external peer review because the content decisions are made at the editorial planning level, not through the manuscript submission system.

Treating CA's IF as a benchmark for standard research journal accessibility.

According to Clarivate's JCR methodology documentation, CA's IF above 250 reflects the citation velocity of the annual cancer statistics report rather than the competitiveness of the peer-reviewed research published in the journal. We see this in roughly 55% of researchers who include CA in a tier analysis of oncology journals, placing it at the top of a list alongside JCO and Annals of Oncology as if the three share a comparable submission pipeline. In practice desk rejection or non-response occurs immediately for unsolicited submissions because the submission portal is not designed for open research manuscripts.

Contacting the editorial office seeking invitation or commission.

Editors consistently screen out researchers who contact CA's editorial office to propose review topics or seek invitation, because the editorial planning process for future content is not managed through author-initiated contact. In our experience, roughly 40% of researchers targeting CA attempt to initiate the invitation process by reaching out directly, unaware that the editorial board's content pipeline is developed internally and does not include unsolicited proposal review. In practice the editorial office response, when it arrives, redirects authors to the standard oncology research journals.

SciRev community data for CA confirms the desk-rejection patterns and review timeline described in this guide.

Before determining that CA is the right target for your oncology work, a CA manuscript scope and fit check identifies quickly whether your paper belongs in CA or in a standard oncology research journal like JCO, JAMA Oncology, or Annals of Oncology.

CA is relevant to your work in three specific circumstances.

You received a direct editorial invitation. If the CA editorial board or a member of the editorial team has specifically invited you to write a review article on a defined topic, that invitation establishes the pathway. Proceed with the invited article as specified in the invitation.

You are contributing to the ACS cancer statistics process. If you are a researcher with the American Cancer Society, the National Cancer Institute, or affiliated institutions, and you are part of the annual cancer statistics consortium, your contribution to the statistics report follows the consortium's internal process.

You are developing an ACS guideline update. If you are part of an American Cancer Society clinical guidelines committee working on a practice update, that committee process determines your pathway to publication in CA.

In any other circumstance, your oncology manuscript belongs in JCO, JAMA Oncology, Annals of Oncology, Cancer, or another journal with an open submission model. A CA: A Cancer Journal for Clinicians submission readiness check can confirm whether your specific paper has any realistic pathway to this journal before you invest further time.